Table 1.
Study demographics
| Item | |
|---|---|
| Median age at date of enrolment in years (IQR) | 66 (63-72) |
| Patients treated with conventionally-fractionated radiotherapy (CFRT)*; n (%) | 31 (97%) |
| Patients treated with hypofractionated radiotherapy (HFRT)*: n (%) | 1 (3%) |
| Median presenting PSA (IQR) in ng/mL | 26.2 (13.4-47) |
| Gleason 6, n (%) | 1 (3%) |
| Gleason 7, n (%) | 12 (37%) |
| Gleason 8, n (%) | 3 (9%) |
| Gleason 9, n (%) | 16 (50%) |
| N0, n (%) | 16 (50%) |
| N1, n (%) | 16 (50%) |
| T1, n (%) | 1 (3%) |
| T2, n (%) | 7 (22%) |
| T3, n (%) | 24 (75%) |
| T4, n (%) | 0 (0%) |
| Subjects on short-course anti-androgen and long-term LHRH analogues | 22 (69%) |
| Subjects on bicalutamide monotherapy | 1 (3%) |
| Subjects on maximum androgen blockade | 9 (28%) |
| Subjects on ADT at time of sampling, n (%)* | 32 (100%)† |
| Subjects with history of abdominal or pelvic surgery, n (%) | 19 (59%) |
| Median body mass index (IQR) | 27 (25-32) |
| Subjects with dyslipidemia and on statins, n (%) | 10 (31%) |
| Subjects with history of diabetes, n (%) | 7 (22%) |
| Subjects with history of hypertension and on medical treatment, n (%) | 13 (41%) |
| Non-smokers/ex-smokers/smokers, n (%) | 19 (59%)/11 (34%)/2 (6%) |
Abbreviations: ADT = androgen deprivation therapy; IQR = interquartile range; PSA = prostate specific antigen.
⁎
CFRT: 70 to 74 Gy to prostate and seminal vesicles (35-37 fractions) or 64 Gy to prostate bed (32 fractions); 50 to 60 Gy to pelvic lymph nodes (35-37 fractions). HFRT: 60 Gy to prostate and seminal vesicles or 55 Gy to prostate bed (20 fractions); 47 Gy to pelvic lymph nodes). †: All patients were on ADT at all sampling timepoints.